[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100491764":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":19,"responsibleParty":42,"collaborators":7,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":7,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":7,"studyType":57,"phases":7,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"REGENXBIO Inc.","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","AAV8 DetectCDx","An in vitro diagnostic assay to detect antibodies to AAV8 in human serum specimens.",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Patient Advocacy","CONTACT","(833) 711-0349","Duchenne@regenxbio.com",[20],{"facility":21,"status":22,"city":23,"state":24,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Rare Disease Research","RECRUITING","Atlanta","Georgia","30329","United States","US",{"type":29,"coordinates":30},"Point",[31,32],-84.38798,33.749,{"lat":32,"lon":31},[35,39],{"name":36,"role":16,"phone":37,"phoneExt":7,"email":38},"Maureen Ikpeoha","470-666-1884","maureen.ikpeoha@rarediseaseresearch.com",{"name":40,"role":41,"phone":7,"phoneExt":7,"email":7},"Han Phan, MD","PRINCIPAL_INVESTIGATOR",{"type":43,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100491764","affinity-beyond-anti-aav8-antibody-assessment-study-of-males-with-dmd-100491764",false,"NCT05683379","AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD","Anti-AAV8 Antibody Assessment Study of Males With Duchenne Muscular Dystrophy Aged 0 to \u003C25 Years","Inclusion Criteria:\n\n* Males at least 0 to \\\u003C25 years of age\n* Diagnosis of DMD\n* Provision of signed and dated informed consent form (ICF) and assent as required per local regulations or requirements\n\nExclusion Criteria:\n\n* Prior participation in a gene therapy trial OR recipient of a gene therapy drug\n* Other inclusion\u002Fexclusion criteria apply","MALE","0 Years","25 Years",{"count":55,"type":56},200,"ESTIMATED","OBSERVATIONAL","This is an observational screening study to evaluate the prevalence of anti-adeno-associated serotype 8 (AAV8) antibodies in participants with Duchenne muscular dystrophy (DMD).",[60],"Duchenne Muscular Dystrophy",[62,60,63],"DMD","Duchenne","2026-06-25",{"date":66,"type":67},"2026-06-30","ACTUAL",{"date":69,"type":67},"2022-12-20",{"date":71,"type":56},"2026-09",{"name":5,"class":6},1]